Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A

Patrick Rowe, Tim Farley, Alexandre Peregoudov, Gilda Piaggio, Simone Boccard, Sihem Landoulsi, Olav Meirik, IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research; Development and Research Training in Human Reproduction, Patrick Rowe, Tim Farley, Alexandre Peregoudov, Gilda Piaggio, Simone Boccard, Sihem Landoulsi, Olav Meirik, IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research; Development and Research Training in Human Reproduction

Abstract

Objectives: To compare rates of unintended pregnancy, method continuation and reasons for removal among women using the 52-mg levonorgestrel (daily release 20 microg) intrauterine device (LNG-IUD) or the copper T 380 A IUD (TCu380A).

Study design: This was an open-label 7-year randomized controlled trial in 20 centres, 11 of which in China. Data on 1884 women with interval insertion of the LNG-IUD and 1871 of the TCu380A were analysed using life tables with 30-day intervals and Cox proportional hazards models.

Results: The cumulative 7-year pregnancy rate of the LNG-IUD was 0.5 (standard error 0.2) per 100, significantly lower than 2.5 (0.4) per 100 of the TCu380A, cumulative method discontinuation rates at 7 years were 70.6 (1.2) and 40.8 (1.3) per 100, respectively. Dominant reasons for discontinuing the LNG-IUD were amenorrhea (26.1 [1.3] per 100) and reduced bleeding (12.5 [1.1] per 100), particularly in Chinese women and, for the TCu380A, increased bleeding (9.9 [0.9] per 100), especially among non-Chinese women. Removal rates for pain were similar for the two intrauterine devices (IUDs). Cumulative rates of removal for symptoms compatible with hormonal side effects were 5.7 (0.7) and 0.4 (0.2) per 100 for the LNG-IUD and TCu380A, respectively, and cumulative losses to follow-up at 7 years were 26.0 (1.4) and 36.9 (1.3) per 100, respectively.

Conclusion: The LNG-IUD and the TCu380A have very high contraceptive efficacy, with the LNG-IUD significantly higher than the TCu380A. Overall rates of IUD removals were higher among LNG-IUD users than TCu380A users. Removals for amenorrhea appeared culturally associated.

Implications: The 52-mg LNG-IUD and the TCu380A have very high contraceptive efficacy through 7 years. As an IUD, the unique side effects of the LNG-IUD are reduced bleeding, amenorrhea and symptoms compatible with hormonal contraceptives.

Keywords: Levonorgestrel IUD; Mirena®; Paragard®; Randomized trial; Seven years; TCu380A.

Copyright © 2016. Published by Elsevier Inc.

Figures

Fig. 1
Fig. 1
Number of women eligible, randomized and followed up in the trial of the 52-mg LNG 20 micro-releasing IUD and the TCu380A IUD.
Fig. 2
Fig. 2
Cumulative rates (per 100) of selected reasons for IUD removal by device in all Chinese and non-Chinese centres.

References

    1. UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development, Research Training in Human Reproduction, Task Force on the Safety and Efficacy of Fertility Regulating Methods The TCu 380 A, TCu 220C, multiload 250 and Nova T IUDs at 3, 5 and 7 years of use - results from three randomized multicenter trials. Contraception. 1990;42:141–158.
    1. United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56:341–352.
    1. Sivin I., Greenslade F., Schmidt F., Waldman S.N. The Population Council; New York: 1992. The copper T 380 intrauterine device: a summary of scientific data.
    1. O'Brien P.A., Kulier R., Helmerhorst F.M., Usher-Patel M., d'Arcangues C. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception. 2008;77:318–327.
    1. Luukkainen T., Allonen H., Hankkamaa M., Holma P., Pyörälä T., Terho J. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-months report of a European multicentre study. Contraception. 1987;36:169–179.
    1. Sivin I., Stern J., Diaz J., Diaz M.M., Faundes A., El Mahgoub S. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu380Ag and levonorgestrel 20mcg/day devices. Contraception. 1987;35:245–255.
    1. Sivin I., El Mahgoub S., McCarthy T., Mishell D.R., Shoupe D., Alvarez F. Long-term contraception with the levonorgestrel 20mcg/day (LNg 20) and the coper T 380Ag intra-uterine devices: a five-year randomized study. Contraception. 1990;42:361–368.
    1. Aiken A.R.A., Trussell J. Vol. 6. 2014. Recent advances in contraception; p. 113. (F1000Prime reports). [ (Accessed 26 June 2015)]
    1. Eisenberg D.L., Schreiber C.A., Turok D.K., Teal S.B., Westhoff C.L., Mitchell D. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92:10–16.
    1. Department of Reproductive Health and Research including UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development, Research Training in Human Reproduction . World Health Organization; Geneva: 2003. Annual technical report 2002.
    1. Tietze C., Lewit S. Recommended procedures for the statistical evaluation of intrauterine contraception. Stud Fam Plann. 1972;4:35–42.
    1. Farley T.M.M. Life-table methods for contraceptive research. Stat Med. 1986;5:475–489.
    1. Meirik O., Rowe P.J., Peregoudov A., Piaggio G., Petzold M., for the IUD Research Group at the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an eight year multicenter randomized comparative trial. Contraception. 2009;80:133–141.
    1. Toivonen J., Luukkainen T., Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 1991;77:261–264.
    1. Lawless J.F. Wiley; New York: 1982. Statistical models and methods for lifetime data.
    1. Cox D.R. Regression models and life tables (with discussion) J R Stat Soc Ser B. 1972;74:187–220.
    1. Andersson K., Odlind V., Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUCDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72.
    1. Sivin I., Stern J., Coutinho E., Mattos C.E.R., El Mahgoub S., Diaz S. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDS. Contraception. 1991;44:473–480.
    1. Faúndes A., Alvarez F., Díaz J. A Latin American experience with levonorgestrel IUD. Ann Med. 1993;25:149–153.
    1. Ronnerdag M., Odlind V. Health effects of long-term use of the intrauterine levonorgestrel releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand. 1999;78:716–721.
    1. Hidalgo M.M., Hidalgo-Regina C., Bahamondes M.V., Monteiro I., Petta C.A., Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80:84–89.
    1. French R., Sorhaindo A.M., Van Vliet H.A.A.M., Mansour D.D., Robinson A.A., Logan S. Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception. Cochrane Database Syst Rev. 2004;(3)
    1. Heinemann K., Reed S., Moehner S., Minh T.D. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European active surveillance study for intrauterine devices. Contraception. 2015;91:280–283.
    1. Diedrich J.T., Madden T., Zhao Q., Peipert J.F. Long-term utilization and continuation of intrauterine devices. Am J Obstet Gynecol. 2015;213:822.e1–822.e6.
    1. Backman T., Rauramo I., Huhtala S., Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol. 2004;190:50–54.
    1. Luukkainen T., Allonen H., Haukkamaa M., Lahteenmaki P., Nilsson C.G., Toivonen J. Five years' experience with levonorgestrel-releasing IUDs. Contraception. 1986;33:139–148.
    1. Indian Council of Medical Research, Task force on IUD Randomized clinical trial with intrauterine devices, (levonorgestrel intrauterine device (LNG), CUT 380Ag, CUT 220C and CUT 200B. A 36-month study. Contraception. 1989;39:37–52.
    1. Nilsson C.G., Lahteenmaki P.L.A., Luukkainen T. Ovarian function in amenorrhoeic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril. 1984;41:52–55.
    1. Madden T., McNicholas C., Zhao Q., Secura G.M., Eisenberg D.L., Peipert J.F. Association of age and parity with intrauterine device expulsion. Obstet Gynecol. 2014;124:718–726.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다